AT9283
- Generic Name
- AT9283
- Drug Type
- Small Molecule
- Chemical Formula
- C19H23N7O2
- CAS Number
- 896466-04-9
- Unique Ingredient Identifier
- XAV9KYN9WL
- Background
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), leukemia (myeloid), and solid tumors.
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 7
- Registration Number
- NCT01431664
- Locations
- 🇬🇧
Royal Marsden Hospital, Surrey, London, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham,, United Kingdom
🇬🇧Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 8
- Registration Number
- NCT01145989
- Locations
- 🇨🇦
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦QEII Health Sciences Center, Halifax, Nova Scotia, Canada
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 33
- Registration Number
- NCT00985868
- Locations
- 🇬🇧
Leeds General Infirmary, Leeds, England, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, England, United Kingdom
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
- Conditions
- MyelofibrosisChronic Myeloid LeukemiaMyelodysplastic SyndromesAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00522990
- Locations
- 🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.